

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1 (original). A pharmaceutical composition comprising a therapeutically effective amount of a Notch protein; and a pharmaceutically acceptable carrier.

2 (original). The composition of claim 1 in which the Notch protein is a human Notch protein.

Claims 3-18 (canceled).

19 (original). A pharmaceutical composition comprising a therapeutically effective amount of a protein, said protein comprising a derivative or analog of a Delta protein, which derivative or analog is characterized by the ability *in vitro*, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell; and a pharmaceutically acceptable carrier.

Claim 20 (canceled).

21 (original). A pharmaceutical composition comprising a therapeutically effective amount of a protein, said protein comprising a derivative or analog of a Serrate protein, which derivative or analog is characterized by the ability *in vitro*, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell; and a pharmaceutically acceptable carrier.

Claim 22 (canceled).

23 (original). A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a Notch protein; and a pharmaceutically acceptable carrier.

Claims 24-28 (canceled).

29 (original). A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a fragment of a Delta protein, which fragment is characterized by the ability *in vitro*, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell; and a pharmaceutically acceptable carrier.

30 (original). A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a fragment of a Serrate protein, which fragment is

characterized by the ability *in vitro*, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell; and a pharmaceutically acceptable carrier.

Claim 31 (canceled).

32 (original). A pharmaceutical composition comprising a therapeutically effective amount of an antibody which binds to a Notch protein; and a pharmaceutically acceptable carrier.

33 (original). A pharmaceutical composition comprising a therapeutically effective amount of a fragment or derivative of an antibody to a Notch protein containing the idiotype of the antibody; and a pharmaceutically acceptable carrier.

34 (original). A method of treating a disease or disorder in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a molecule which antagonizes the function of a Notch protein.

Claim 35-45 (canceled)

46 (original). A method of treating a disease or disorder in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a molecule which promotes the function of a Notch protein.

Claims 47-89 (canceled).